Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) Operating Margin (2022 - 2025)

Historic Operating Margin for InMed Pharmaceuticals (INM) over the last 5 years, with Q3 2025 value amounting to 162.54%.

  • InMed Pharmaceuticals' Operating Margin fell 253500.0% to 162.54% in Q3 2025 from the same period last year, while for Sep 2025 it was 167.4%, marking a year-over-year decrease of 210800.0%. This contributed to the annual value of 160.77% for FY2025, which is 175000.0% up from last year.
  • According to the latest figures from Q3 2025, InMed Pharmaceuticals' Operating Margin is 162.54%, which was down 253500.0% from 139.49% recorded in Q2 2025.
  • Over the past 5 years, InMed Pharmaceuticals' Operating Margin peaked at 20.99% during Q2 2023, and registered a low of 1626.64% during Q4 2021.
  • Its 5-year average for Operating Margin is 463.0%, with a median of 186.09% in 2024.
  • As far as peak fluctuations go, InMed Pharmaceuticals' Operating Margin surged by 12456200bps in 2023, and later plummeted by -1375500bps in 2024.
  • Quarter analysis of 5 years shows InMed Pharmaceuticals' Operating Margin stood at 1626.64% in 2021, then surged by 71bps to 471.26% in 2022, then surged by 72bps to 132.64% in 2023, then tumbled by -53bps to 202.75% in 2024, then grew by 20bps to 162.54% in 2025.
  • Its Operating Margin stands at 162.54% for Q3 2025, versus 139.49% for Q2 2025 and 169.43% for Q1 2025.